Gold Nanoparticles Bearing Functional Anti-Cancer Drug and Anti-Angiogenic Agent: A "2 in 1" System with Potential Application in Cancer Therapeutics

2005 ◽  
Vol 1 (2) ◽  
pp. 224-228 ◽  
Author(s):  
Priyabrata Mukherjee ◽  
Resham Bhattacharya ◽  
Debabrata Mukhopadhyay
2017 ◽  
Vol 5 (5) ◽  
pp. 872-886 ◽  
Author(s):  
Jingyi Zong ◽  
Steven L. Cobb ◽  
Neil R. Cameron

This review provides an overview of the current methods used for preparing peptide-functionalized GNPs, and discusses the key properties of this class of biomaterial. In particular, their potential application in areas of sensing, targeted drug delivery, anti-cancer therapeutics and oligonucleotide delivery are discussed.


Pharmaceutics ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 261
Author(s):  
Wei Mao ◽  
Sol Lee ◽  
Ji Un Shin ◽  
Hyuk Sang Yoo

Surface initiated atom transfer radical polymerization (SI-ATRP) documented a simple but efficient technique to grow a dense polymer layer on any surface. Gold nanoparticles (AuNPs) give a broad surface to immobilize sulfhyryl group-containing initiators for SI-ATRP; in addition, AuNPs are the major nanoparticulate carriers for delivery of anti-cancer therapeutics, since they are biocompatible and bioinert. In this work, AuNPs with a disulfide initiator were polymerized with sulfoethyl methacrylate by SI-ATRP to decorate the particles with anionic corona, and branched polyethyeleneimine (PEI) and siRNA were sequentially layered onto the anionic corona of AuNP by electrostatic interaction. The in vitro anti-cancer effect confirmed that AuNP with anionic corona showed higher degrees of apoptosis as well as suppression of the oncogene expression in a siRNA dose-dependent manner. The in vivo study of tumor-bearing nude mice revealed that mice treated with c-Myc siRNA-incorporated AuNPs showed dramatically decreased tumor size in comparison to those with free siRNA for 4 weeks. Furthermore, histological examination and gene expression study revealed that the decorated AuNP significantly suppressed c-Myc expression. Thus, we envision that the layer-by-layer assembly on the anionic brushes can be potentially used to incorporate nucleic acids onto metallic particles with high transfection efficiency.


2009 ◽  
Vol 56 (4) ◽  
pp. 703-708 ◽  
Author(s):  
Ching-Ming Wu ◽  
Ping-Ching Wu ◽  
Yun-Han Wang ◽  
Tsung-Ju Li ◽  
Li-Xing Yang ◽  
...  

2009 ◽  
Vol 19 (16) ◽  
pp. 2310 ◽  
Author(s):  
Chiyoung Park ◽  
Hyewon Youn ◽  
Hana Kim ◽  
Taiho Noh ◽  
Yeon Hee Kook ◽  
...  

2021 ◽  
Author(s):  
Celina Yang

Gold nanoparticles (GNPs) have been extensively used in cancer research due to their abilities as anti-cancer drug carriers for chemotherapy and as dose enhancers in radiotherapy. Although most GNP research in the past involved cytoplasm localized GNPs, it is predicted that therapy response can be enhanced if GNPs can be effectively targeted into the nucleus. A strategy for designing a GNP-peptide complex for targeting the nucleus will be presented. Three different sequences of peptides (CKKKKKKGGAGDMFG, CGGRKKRRGRRRAP, CALNN) were conjugated onto GNPs. The first peptide was used to stabilize the complex, the second peptide to enhance uptake into the cell, while the third peptide was used to induce nuclear delivery. With nuclear targeting, more damage can be caused to the DNP of cancer cells upon irradiation. This research will establish a more successful NP-based platform that combines treatment modalities and more effectively approach cancer treatment.


F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 1024 ◽  
Author(s):  
Jung-Eun Park ◽  
David Hymel ◽  
Terrence R. Burke, Jr. ◽  
Kyung S. Lee

Although significant levels of side effects are often associated with their use, microtubule-directed agents that primarily target fast-growing mitotic cells have been considered to be some of the most effective anti-cancer therapeutics. With the hope of developing new-generation anti-mitotic agents with reduced side effects and enhanced tumor specificity, researchers have targeted various proteins whose functions are critically required for mitotic progression. As one of the highly attractive mitotic targets, polo-like kinase 1 (Plk1) has been the subject of an extensive effort for anti-cancer drug discovery. To date, a variety of anti-Plk1 agents have been developed, and several of them are presently in clinical trials. Here, we will discuss the current status of generating anti-Plk1 agents as well as future strategies for designing and developing more efficacious anti-Plk1 therapeutics.


Nanoscale ◽  
2020 ◽  
Vol 12 (28) ◽  
pp. 14996-15020
Author(s):  
Wei Mao ◽  
Young Ju Son ◽  
Hyuk Sang Yoo

Various gold nanoparticles have been explored as cancer therapeutics because they can be widely engineered for use as efficient drug carriers and diagnostic agents, and in photo-irradiation therapy.


2017 ◽  
Vol 46 (43) ◽  
pp. 14831-14838 ◽  
Author(s):  
Huitao Fan ◽  
Xiaojing Xing ◽  
Yuhan Yang ◽  
Bo Li ◽  
Congcong Wang ◽  
...  

A novel nanocarrier based on MWCNTs@CoFe2O4@mSiO2 was proposed, and its potential application for targeted cancer therapy was highlighted.


2009 ◽  
Vol 13 (06) ◽  
pp. 36-54 ◽  

"Off-The-Shelf" Stem Cell Treatment for Heart Failure. Cytopia Cancer Program Reaches Important Milestone at Cancer Therapeutics CRC. Starpharma and Elanco Agree to Develop New Products. China Sky One Medical, Inc. Achieves Significant Breakthrough In Sudden Cardiac Death (SCD) Early Examination Kit. Roche Applied Science Opens Application Support Center in Shanghai. Luminex Expands Globally and Opens Facility in People's Republic of China. Genesis Pharmaceuticals Launches Three New TCM Products. China Sky One Medical, Inc. to Develop New Anti-Cancer Drug with Taiwan Golden Biotechnology Corp. Solvay Pharmaceuticals Announces Strategic Partnership with HUYA to Access New Drug Candidates From China. Sinovac Receives $US12.9 mn Purchase Order for Healive® from China's Ministry of Public Health. GE Launches Lullaby Warmer for Newborn in India. SymBio Pharmaceuticals Limited and Eisai Co., Ltd. Conclude License Agreement for Bendamustine Hydrochloride (SyB L-0501) in Korea and Singapore. Aperio Expands Global Digital Pathology Presence with New Subsidiary in Asia. Valeant Pharmaceuticals Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange. Genome Institute of Singapore and Roche NimbleGen Develop Rapid Approach to Identify H1N1 Virus Mutations and Resistance to Drugs.


2010 ◽  
Vol 82 (2) ◽  
pp. 355-362 ◽  
Author(s):  
Tatiane A. Jó ◽  
Denise F.S. Petri ◽  
Leila M. Beltramini ◽  
Neoli Lucyszyn ◽  
Maria Rita Sierakowski

Sign in / Sign up

Export Citation Format

Share Document